Citadel Advisors
MIRM icon

Citadel Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Citadel Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$97.2M Buy
1,052,048
+211,828
+25% +$19.9M 0.02% 826
2025
Q4 		$66.4M Sell
840,220
-200,324
-19% -$14.4M 0.01% 1167
2025
Q3 		$76.3M Sell
1,040,544
-365,808
-26% -$23.3M 0.01% 1038
2025
Q2 		$71.6M Sell
1,406,352
-39,643
-3% -$1.77M 0.01% 982
2025
Q1 		$65.1M Sell
1,445,995
-65,188
-4% -$3.07M 0.01% 949
2024
Q4 		$62.5M Buy
1,511,183
+119,774
+9% +$4.99M 0.01% 1085
2024
Q3 		$54.3M Sell
1,391,409
-194,215
-12% -$7.75M 0.01% 1140
2024
Q2 		$54.2M Buy
1,585,624
+193,118
+14% +$5.06M 0.01% 1087
2024
Q1 		$35M Sell
1,392,506
-50,306
-3% -$1.38M 0.01% 1508
2023
Q4 		$42.6M Sell
1,442,812
-274,445
-16% -$8.31M 0.01% 1305
2023
Q3 		$53.7M Buy
1,717,257
+287,412
+20% +$7.87M 0.01% 1015
2023
Q2 		$37M Buy
1,429,845
+60,500
+4% +$1.61M 0.01% 1297
2023
Q1 		$32.9M Sell
1,369,345
-39,214
-3% -$894K 0.01% 1450
2022
Q4 		$27.5M Buy
1,408,559
+483,382
+52% +$9.55M 0.01% 1633
2022
Q3 		$19.4M Buy
925,177
+495,330
+115% +$11.9M ﹤0.01% 1901
2022
Q2 		$8.37M Buy
429,847
+96,819
+29% +$2.28M ﹤0.01% 2917
2022
Q1 		$7.33M Buy
333,028
+206,602
+163% +$4.21M ﹤0.01% 3466
2021
Q4 		$2.02M Buy
126,426
+39,948
+46% +$621K ﹤0.01% 6218
2021
Q3 		$1.72M Buy
+86,478
New +$1.41M ﹤0.01% 6743
2021
Q1 		– Sell
-15,437
Closed -$269K – 13525
2020
Q4 		$269K Sell
15,437
-11,442
-43% -$225K ﹤0.01% 9253
2020
Q3 		$518K Buy
26,879
+13,742
+105% +$295K ﹤0.01% 7245
2020
Q2 		$256K Buy
+13,137
New +$220K ﹤0.01% 8171

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors's MIRM Position: Q1 2026 in Review

Citadel Advisors increased its Mirum Pharmaceuticals (MIRM) stake by 25% in Q1 2026, buying an estimated $19.9M and bringing the position to 1,052,048 shares worth $97.2M. The position accounts for 0.02% of the portfolio, ranked #826.

Citadel Advisors first reported a position in MIRM in Q2 2020 and has held it in 22 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Citadel Advisors held 1,052,048 shares of Mirum Pharmaceuticals worth $97.2M as of Q1 2026.
  • Citadel Advisors bought 211,828 Mirum Pharmaceuticals shares in Q1 2026, an estimated $19.9M.
  • Mirum Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #826 holding.
  • Citadel Advisors first reported a position in Mirum Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.